Using 3D wearable technology to predict breast cancer treatment outcomes
Official title: 3D wearable NIR spectral tomography for early prediction of breast cancer’s residual cancer burden after neoadjuvant chemotherapy
Funded at Dartmouth College · NIH-10939474 · Data updated 2026-11-12
This study is testing a new, easy-to-use imaging method that helps doctors see how well chemotherapy is working for breast cancer patients, so they can better understand how much cancer is left after treatment and improve chances for a healthier future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dartmouth College NIH-funded |
| Lab location | 1 site (Hanover, United States) |
| Project start | July 10, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $549,536 |
| NIH project number | 1R01CA291967-01 |
| Project ID | NIH-10939474 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with breast cancer who are about to begin neoadjuvant chemotherapy.
✕Less likely to help
Patients who have already completed their chemotherapy or those with advanced metastatic breast cancer may not benefit from this research.
What this research studies
This research investigates a new method using near-infrared spectral tomography (NIRST) to predict how much cancer remains in breast cancer patients after they undergo neoadjuvant chemotherapy. The approach is noninvasive, portable, and cost-effective, allowing for quick assessments of tumor response without the need for radiation or contrast agents. By capturing subtle changes in breast tissue, this technology aims to provide early insights into treatment effectiveness, potentially improving long-term survival rates for patients. The study will involve monitoring patients during their treatment to correlate imaging results with clinical outcomes.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate predictions of treatment effectiveness, ultimately improving survival outcomes for breast cancer patients.
How similar studies have gone: Previous studies have shown promising results with NIRST technology in monitoring tumor responses, indicating potential for success in this novel application.
Where this research is happening
-
Dartmouth College
Hanover, United States Active
Researchers
- Principal investigator: Jiang, Shudong — Dartmouth College
- Study coordinator: Jiang, Shudong
Related research
Other NIH-funded projects on the same topics.
-
Magnetic resonance fingerprinting to gauge chemotherapy response in breast cancer
A patient-facing look at using a special MRI method (MRF) to see early whether breast cancer is responding to preliminary chemotherapy.
-
3D wearable NIR imaging to predict breast cancer response during treatment
A noninvasive, portable 3D wearable optical test (NIRS tomography) will be used to spot early signs of how breast cancer is responding to chemotherapy, helping guide treatment for patients.
-
MRI fingerprinting to spot early breast tumor response to chemotherapy given before surgery
This project uses a new MRI method to find early changes in breast tumors during chemotherapy given before surgery so doctors can change treatment sooner if needed.
-
Improving how we track breast cancer chemotherapy with 3D imaging
This project aims to develop a new 3D ultrasound method to see how well chemotherapy is working for breast cancer patients before surgery.
-
New Wearable Imaging to See How Breast Cancer Responds to Chemotherapy
This project is developing a new wearable imaging device to help doctors see very early if breast cancer treatment is working for patients receiving chemotherapy before surgery.
-
How pre-surgery chemotherapy affects breast cancer spread
This study is looking at how chemotherapy for breast cancer might sometimes help cancer cells spread to other parts of the body, and it aims to understand the role of certain immune cells in this process, which could lead to better treatment options for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.